{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-020715","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2021-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.619689+00:00","generated_at":"2026-06-29T08:31:21.166066+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vaxart appoints Julie M. Cherrington, Ph.D. to Board of Directors","bullets":["Dr. Cherrington appointed to Vaxart's Board and Audit Committee effective August 20, 2021.","She receives annual cash retainers: $40k for Board, $7.5k for Audit Committee, plus time-based stock option for 65,700 shares vesting over 3 years.","Dr. Cherrington is CEO of QUE Oncology, has held leadership roles at Gilead, SUGEN, and several oncology biotechs.","Vaxart is developing oral tablet vaccines for COVID-19 and norovirus; Phase II COVID-19 trials expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-020715","json":"https://secwatch.observer/filing/0001437749-21-020715.json","markdown":"https://secwatch.observer/filing/0001437749-21-020715.md","text":"https://secwatch.observer/filing/0001437749-21-020715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774921020715/0001437749-21-020715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774921020715/vxrt20210820_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:31:21.166066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91224780d1","claim":"Julie M. Cherrington was appointed as Director at Vaxart, Inc..","evidence_excerpt":"On August 20, 2021, the Board of Directors (the “ Board ”) of Vaxart, Inc. (the “ Company ”) appointed Julie M. Cherrington, Ph.D., to serve on our Board until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774921020715/0001437749-21-020715-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}